Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I

Molecular Endocrinology

Volumn 22, Issue 5, 2008, Pages 1226-1237

  Maile, Laura A ^a,b   Capps, Byron E ^a   Miller, Emily C ^a   Allen, Lee B ^a   Veluvolu, Umadevi ^a   Aday, Ariel W ^a   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; GELATINASE A; GLUCOSE; PROTEIN SHC; PROTEINASE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; SOMATOMEDIN C;

ARTICLE; BINDING SITE; CELL GROWTH; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; SENSITIVITY ANALYSIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIGENS, CD47; CELL PROLIFERATION; GLUCOSE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SWINE;

EID: 43049104174     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0552     Document Type: Article

References (39)

1. Hardie DG 2004 The AMP-activated protein kinase pathway: new players upstream and downstream. J Cell Sci 117:5479-5487
2. Gulati P, Thomas G 2007 Nutrient sensing in the mTOR/ S6K1 signalling pathway. Biochem Soc Trans 35:236-238
3. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR 2007 Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 148:2435-2443
4. Ling Y, Maile LA, Lieskovska J, Badley-Clarke J, Clemmons DR 2005 Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol Biol Cell 16:3353-3364
5. Maile LA, Clemmons DR 2002 Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277:8955-8960
6. Lieskovska J, Ling Y, Badley-Clarke J, Clemmons DR 2006 The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells. J Biol Chem 281:25041-25053
7. Maile LA, Badley-Clarke J, Clemmons DR 2003 The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Mol Biol Cell 14:3519-3528
8. Campbell M, Allen WE, Silversides JA, Trimble ER 2003 Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-β receptor potentiates vascular smooth muscle cell chemotaxis. Diabetes 52:519-526
9. Campbell M, Allen WE, Sawyer C, Vanhaesebroeck B, Trimble ER 2004 Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res 95:380-388
10. Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, Brown EJ, Ullrich A, Buhring HJ 1999 Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94:3633-3643
11. Vernon-Wilson EF, Kee WJ, Willis AC, Barclay AN, Simmons DL, Brown MH 2000 CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα1. Eur J Immunol 30:2130-2137
12. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM 2004 Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145:5646-5655
13. McLennan SV, Martell SK, Yue DK 2002 Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 51:2612-2618
14. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE 2002 Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45:268-275
15. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, Yue DK 2000 Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 77:S81-S87
16. McLennan SV, Martell SY, Yue DK 2000 High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia 43:642-648
17. McLennan SV, Yue DK, Turtle JR 1998 Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 79:293-298
18. Kleifeld O, Kotra LP, Gervasi DC, Brown S, Bernardo MM, Fridman R, Mobashery S, Sagi I 2001 X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme. J Biol Chem 276:17125-17131
19. Ikejiri M, Bernardo MM, Meroueh SO, Brown S, Chang M, Fridman R, Mobashery S 2005 Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 70:5709-5712
20. Ikejiri M, Bernardo MM, Bonfil RD, Toth M, Chang M, Fridman R, Mobashery S 2005 Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 280:33992-34002
21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M 1994 A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65
22. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI 1995 Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331-5338
23. Subramanian S, Boder ET, Discher DE 2007 Phylogenetic divergence of CD47 interactions with human signal regulatory protein α reveals locus of species specificity. Implications for the binding site. J Biol Chem 282:1805-1818
24. Solomon A, Rosenblum G, Gonzales PE, Leonard JD, Mobashery S, Milla ME, Sagi I 2004 Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-α-converting enzyme and matrix metalloproteinases despite their high structural similarity. J Biol Chem 279:31646-31654
25. Nagase H 1998 Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 8:179-186
26. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR 2006 An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 21:2406-2416
27. Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, Leehey DJ 2001 High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-β1. Exp Nephrol 9:249-257
28. McGinn S, Poronnik P, Gallery ED, Pollock CA 2004 The effects of high glucose and atorvastatin on endothelial cell matrix production. Diabet Med 21:1102-1107
29. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA 1996 Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 271:21-24
30. Maile LA, Clemmons DR 2003 Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Circ Res 93:925-931
31. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP 2000 Role of CD47 as a marker of self on red blood cells. Science 288:2051-2054
32. Lundberg P, Koskinen C, Baldock PA, Lothgren H, Stenberg A, Lerner UH, Oldenborg PA 2007 Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPα-interaction. Biochem Biophys Res Commun 352:444-448
33. Cooper D, Lindberg FP, Gamble JR, Brown EJ, Vadas MA 1995 Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc Natl Acad Sci USA 92:3978-3982
34. Johansen ML, Brown EJ 2007 Dual regulation of SIRPα phosphorylation by integrins and CD47. J Biol Chem 282:24219-24230
35. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Clemmons DR 2006 IGF-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the β3 subunit of αVβ3. Mol Endocrinol 20:881-892
36. Ross R 1971 The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 50:172-186
37. Nam TJ, Busby Jr WH, Rees C, Clemmons DR 2000 Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 141:1100-1106
38. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Ling Y, Clemmons DR 2005 The heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol 20:405-411
39. Ling Y, Maile LA, Clemmons DR 2003 Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulinlike growth factor I receptor. Mol Endocrinol 17:1824-1833